← Browse by Condition
Medical Condition

stargardt disease

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for stargardt disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — stargardt disease Clinical Trials

How many clinical trials are currently recruiting for stargardt disease?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for stargardt disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for stargardt disease?
stargardt disease research spans Phase 1 (2 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a stargardt disease clinical trial?
Eligibility criteria for stargardt disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
1
Top Sponsors
University of Rochester 1 trial
Foundation Fighting Blindness 1 trial
Ray Therapeutics, Inc. 1 trial

Recruiting Clinical Trials

NCT06319872 Phase 1
Recruiting
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Enrollment
15 pts
Location
United States
Sponsor
University of Rochester
View Trial →
NCT02435940
Recruiting
Inherited Retinal Degenerative Disease Registry
Enrollment
20,000 pts
Location
United States
Sponsor
Foundation Fighting Blindness
View Trial →
NCT07439887 Phase 1, Phase 2
Recruiting
Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
Enrollment
18 pts
Location
United States
Sponsor
Ray Therapeutics, Inc.
View Trial →

Related Conditions

retinitis pigmentosa (2) alcohol use disorder (1) retinal dystrophies (1) age related macular degeneration (1) eye diseases hereditary (1) retinal disease (1) achromatopsia (1) bardet biedl syndrome (1) bassen kornzweig syndrome (1) batten disease (1) best disease (1) choroidal dystrophy (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology